Investigational drug · Phase 2
Elezanumab
Also called: ABT-555
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Spinal Cord Injury (SCI).
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
7
Any phase or sponsor naming "Elezanumab"
First trial start
2020
Sep 6, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Elezanumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Spinal Cord Injury (SCI)
Largest trials
Live from ClinicalTrials.gov: studies naming "Elezanumab" as an intervention, largest first.
- A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple SclerosisPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03737851 · 208 participants · Start Dec 11, 2018 · Primary completion Aug 9, 2021
Drug: elezanumab; placebo · For: Multiple Sclerosis (MS)
Sites: Birmingham, Alabama; Phoenix, Arizona; Berkeley, California · 49 sites in all
- A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple SclerosisPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03737812 · 123 participants · Start Feb 27, 2019 · Primary completion Jan 15, 2021
Drug: elezanumab; placebo · For: Multiple Sclerosis (MS)
Sites: Phoenix, Arizona; Berkeley, California; Carlsbad, California · 37 sites in all
- A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic StrokePivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT04309474 · 121 participants · Start Nov 9, 2020 · Primary completion Apr 18, 2024
Drug: Elezanumab; Placebo · For: Acute Ischemic Stroke
Sites: Phoenix, Arizona; Long Beach, California; Washington D.C., District of Columbia · 42 sites in all
AbbVieAbbVie (ABBV)
NCT04295538 · 60 participants · Start Sep 6, 2020 · Primary completion Jan 26, 2026
Drug: Elezanumab; Placebo · For: Spinal Cord Injury (SCI)
Sites: Sacramento, California; Atlanta, Georgia; Chicago, Illinois · 41 sites in all
AbbVieAbbVie (ABBV)
NCT02601885 · 20 participants · Start Oct 18, 2016 · Primary completion Apr 20, 2018
Drug: ABT-555 · For: Multiple Sclerosis
Sites: Orlando, Florida; Lenexa, Kansas; Baltimore, Maryland · 8 sites in all
AbbVieAbbVie (ABBV)
NCT02606630 · 4 participants · Start Oct 2015 · Primary completion Dec 2015
Drug: ABT-555 · For: Multiple Sclerosis
Sites: London, United Kingdom; Whitechapel, United Kingdom
- Expanded Access to ElezanumabNo longer available
AbbVieAbbVie (ABBV)
NCT04278235
Drug: Elezanumab · For: Acute Spinal Cord Injury (SCI)
Newest research
PubMed records naming it or its code names, newest first.
- Clinical stage anti-RGMa monoclonal antibody elezanumab promotes bladder recovery and neuroplasticity after traumatic spinal cord injury.
Mothe AJ, Hassouna M, Ahuja C, et al. · Biomed Pharmacother 2026
- Elezanumab for the treatment of spinal cord injury: assessing the clinical development journey to date.
Mothe AJ, Monnier PP, Tator CH, et al. · Expert Opin Investig Drugs 2026
- Elezanumab Accelerates Post-Injury Regeneration of Olfactory Sensory Neurons in a Methimazole-Induced Mouse Model.
Mori E, Ueha R, Tanaka H, et al. · Int Forum Allergy Rhinol 2025
- Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis.
Cree BAC, Freedman MS, Gold M, et al. · Ann Neurol 2025
- Repulsive Guidance Molecule-A as a Therapeutic Target Across Neurological Disorders: An Update.
Tseriotis VS, Liampas A, Lazaridou IZ, et al. · Int J Mol Sci 2025
- Neutralizing RGMa with Elezanumab Promotes Cerebroprotection and Recovery in Rabbit Middle Cerebral Artery Occlusion.
Jacobson PB, Mothe A, Levy A, et al. · Transl Stroke Res 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.